The SETD7 setd7 (Catalog #MBS602725) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The SET7/SET9 reacts with Human, Monkey, Mouse, Rat and may cross-react with other species as described in the data sheet.
Suitable for use in Western Blot.
Dilution: Western Blot: 1:1000. Researchers should empirically determine the suitability of the SETD7 setd7 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The SETD7 setd7 product has the following accession number(s) (GI #111309205) (Uniprot Accession #Q8WTS6). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
SET7/SET9 is a member of the SET domain-containing family, and can specifically methylate Lys4 on histone H3 (1). Like most other lysine-directed histone methyltransferases, it contains a conserved catalytic SET domain originally identified in the Drosophila Su(var)3-9, Enhancer of zeste and Trithorax proteins. Histone methylation is a major determinant for the formation of active and inactive regions of the genome and is crucial for the proper programming of the genome during development (2,3). Methylation of histone H3 Lys4 enhances transcriptional activation by coordinating the recruitment of BPTF, a component of the NURF chromatin remodeling complex, and WDR5, a component of multiple histone methyltransferase complexes (4,5). In addition, methylation of lysine 4 blocks transcriptional repression by inhibiting the binding of the NURD histone deacetylation complex to the amino-terminal tail of histone H3 and interfering with SUV39H1-mediated methylation of histone H3 Lys9 (1). SET7/SET9 is highly active on free histone H3, but only very weakly methylates H3 within nucleosomes (1). Besides histones, SET7/SET9 also methylates Lys189 of the TAF10, a member of the TFIID transcription factor complex, and Lys372 of the p53 tumor suppressor protein (6,7). Methylation of TAF10 stimulates transcription in a promoter-specific manner by increasing the affinity of TAF10 for RNA polymerase II, which may potentiate pre-initiation complex formation (6). Methylation of p53 at Lys372 increases protein stability and leads to upregulation of target genes such as p21. Thus the loss of SET7/SET9 may represent another mechanism for the inactivation of p53 in human cancers (7). Specificity/Sensitivity: SET7/SET9 (C24B1) Rabbit mAb detects endogenous levels of total SET7/SET9 protein. This antibody does not cross-react with other SET domain-containing proteins.
Immunogen: Synthetic peptide (KLH-coupled) corresponding to the amino terminus of the human SET7/SET9 protein. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing SETD7 are readily searchable from our website. Different antibodies against the same target such as SETD7 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. |
Blog 
